“Magic Bullets” at the center stage of immune therapy: a special issue on therapeutic antibodies

References

[1] An Z (2009) Therapeutic monoclonal antibodies: from bench to clinic. Hoboken, Wiley

[2] An Z (2010) Monoclonal antibodies—a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1:319–330

[3] Bardwell PD, Staron MM, Liu J, Tao Q, Scesney S, Bukofzer G, Rodriguez LE, Choi CH, Wang J, Chang Q, (2017) Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig. Protein Cell 9:121–129

[4] Emmons C, Hunsicker LG (1987) Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use. Iowa Med 77:78–82

[5] Kang C, Xia L, Chen Y, Zhang T, Wang Y, Zhou B, You M, Yuan Q, Tzeng CM, An Z, (2017) A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys. Protein Cell 9:130–134

[6] Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497

[7] Liu L (2017) Pharmacokinetics of monoclonal antibodies and Fcfusion proteins. Protein Cell 9:15–32

[8] Mimura Y, Katoh T, Saldova R, O’Flaherty R, Izumi T, Mimura-Kimura Y, Utsunomiya T, Mizukami Y, Yamamoto K, Matsumoto T, (2017) Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy. Protein Cell 9:47–62

[9] Simeon R, Chen Z (2017) In vitro-engineered non-antibody protein therapeutics. Protein Cell 9:3–14

[10] Strohl WR (2017) Current progress in innovative engineered antibodies. Protein Cell 9:86–120

[11] Tan S, Liu K, Chai Y, Zhang CW, Gao S, Gao GF, Qi J (2017) Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell 9:135–139

[12] Tsuchikama K, An Z (2016) Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9:33–46

[13] Wang X, An Z, Luo W, Xia N, Zhao Q (2017a) Molecular and functional analysis of monoclonal antibodies in support of biologics development. Protein Cell 9:74–85

[14] Wang X, Mathieu M, Brezski RJ (2017b) IgG Fc engineering to modulate antibody effector functions. Protein Cell 9:63–73

RIGHTS & PERMISSIONS

2017 The Author(s) 2017. This article is an open access publication